304 related articles for article (PubMed ID: 11735450)
1. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
Oh HK; Lee JM; Byun TH; Park SY; Kim YH
Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
[TBL] [Abstract][Full Text] [Related]
3. Immunopurification of human factor VIII/vWF complex from plasma.
Mejan O; Fert V; Delezay M; Delaage M; Cheballah R; Bourgois A
Thromb Haemost; 1988 Jun; 59(3):364-71. PubMed ID: 3142074
[TBL] [Abstract][Full Text] [Related]
4. Characterization of monoclonal immunoglobulin a and g against shiga toxin binding subunits produced by intranasal immunization.
Tanikawa T; Ishikawa T; Maekawa T; Kuronane K; Imai Y
Scand J Immunol; 2008 Oct; 68(4):414-22. PubMed ID: 18782271
[TBL] [Abstract][Full Text] [Related]
5. Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII.
Sandberg H; Kannicht C; Stenlund P; Dadaian M; Oswaldsson U; Cordula C; Walter O
Thromb Res; 2012 Nov; 130(5):808-17. PubMed ID: 23010293
[TBL] [Abstract][Full Text] [Related]
6. Kinetic parameters of monoclonal antibodies ESH2, ESH4, ESH5, and ESH8 on coagulation factor VIII and their influence on factor VIII activity.
Egler C; Albert T; Brokemper O; Zabe-Kühn M; Mayer G; Oldenburg J; Schwaab R
J Mol Recognit; 2009; 22(4):301-6. PubMed ID: 19266540
[TBL] [Abstract][Full Text] [Related]
7. Characterization of four monoclonal antibodies to factor VIII coagulant protein and their use in immunopurification of factor VIII.
Croissant MP; van de Pol H; Lee HH; Allain JP
Thromb Haemost; 1986 Dec; 56(3):271-6. PubMed ID: 2436329
[TBL] [Abstract][Full Text] [Related]
8. Identification of a thrombin-interactive site within the FVIII A2 domain that is responsible for the cleavage at Arg372.
Nogami K; Saenko EL; Takeyama M; Giddings JC; Yoshioka A; Shima M
Br J Haematol; 2008 Feb; 140(4):433-43. PubMed ID: 18081893
[TBL] [Abstract][Full Text] [Related]
9. Immunoaffinity purification of factor VIII complex.
Hornsey VS; Griffin BD; Pepper DS; Micklem LR; Prowse CV
Thromb Haemost; 1987 Feb; 57(1):102-5. PubMed ID: 3109055
[TBL] [Abstract][Full Text] [Related]
10. Development and applications of surface plasmon resonance-based von Willebrand factor-collagen binding assay.
Saenko E; Kannicht C; Loster K; Sarafanov A; Khrenov A; Kouiavskaia D; Shima M; Ananyeva N; Schwinn H; Gruber G; Josic D
Anal Biochem; 2002 Mar; 302(2):252-62. PubMed ID: 11878805
[TBL] [Abstract][Full Text] [Related]
11. Immunoaffinity purification of factor VIII.
Weinstein RE
Ann Clin Lab Sci; 1989; 19(2):84-91. PubMed ID: 2502062
[TBL] [Abstract][Full Text] [Related]
12. von Willebrand factor protects the Ca2+-dependent structure of the factor VIII light chain.
Takeyama M; Nogami K; Okuda M; Shima M
Br J Haematol; 2009 Sep; 146(5):531-7. PubMed ID: 19594746
[TBL] [Abstract][Full Text] [Related]
13. Human interleukin 4 receptor complex: neutralization effect of two monoclonal antibodies.
Taremi SS; Prosise WW; Rajan N; O'Donnell RA; Le HV
Biochemistry; 1996 Feb; 35(7):2322-31. PubMed ID: 8652573
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of an affinity chromatography step using a peptide ligand for cGMP production of factor VIII.
Kelley BD; Tannatt M; Magnusson R; Hagelberg S; Booth J
Biotechnol Bioeng; 2004 Aug; 87(3):400-12. PubMed ID: 15281114
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of the Factor VIII yield in mammalian cell cultures by reducing the membrane bound fraction.
Kolind MP; Nørby PL; Berchtold MW; Johnsen LB
J Biotechnol; 2011 Feb; 151(4):357-62. PubMed ID: 21219947
[TBL] [Abstract][Full Text] [Related]
16. Application of a novel affinity adsorbent for the capture and purification of recombinant factor VIII compounds.
McCue JT; Selvitelli K; Walker J
J Chromatogr A; 2009 Nov; 1216(45):7824-30. PubMed ID: 19800068
[TBL] [Abstract][Full Text] [Related]
17. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
Khrenov AV; Ananyeva NM; Saenko EL
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
[TBL] [Abstract][Full Text] [Related]
18. Optical biosensor-based characterization of anti-double-stranded DNA monoclonal antibodies as possible new standards for laboratory tests.
Buhl A; Page S; Heegaard NH; von Landenberg P; Luppa PB
Biosens Bioelectron; 2009 Sep; 25(1):198-203. PubMed ID: 19632822
[TBL] [Abstract][Full Text] [Related]
19. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
20. Two-dimensional fluorescence difference gel electrophoresis for comparison of affinity and non-affinity based downstream processing of recombinant monoclonal antibody.
Grzeskowiak JK; Tscheliessnig A; Toh PC; Chusainow J; Lee YY; Wong N; Jungbauer A
J Chromatogr A; 2009 Jun; 1216(24):4902-12. PubMed ID: 19423113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
